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Within the concept of reduced-intensity stem cell transplantation (RIST) there is a wide range of different
regimens used, and little information is available on the clinical impact of chimerism status in patients condi-
tioned with a busulfan-containing regimen. Therefore, we retrospectively reviewed lineage-specific chimerism
and the subsequent clinical outcome in 117 patients (median age, 55 years; range: 29-68) who underwent bu-
sulfan-containing RIST. The conditioning regimen consisted of busulfan (oral 8 mg/kg or i.v. 6.4 mg/kg) and flu-
darabine (180mg/m2, n5 64) or cladribine (0.66mg/kg, n5 53), with or without 2-4 Gy total-body irridiation
(TBI) (n5 26) or antihuman T-lymphocyte immunoglobulin (ATG; 5-10 mg/kg; n5 31). Chimerism was eval-
uated with peripheral blood samples taken on days 30, 60, and 90 after transplantation by polymerase chain
reaction (PCR)-based amplification of polymorphic short tandem repeat regions. Themedian follow-up of sur-
viving patients was 1039 days (153-2535). The percent donor-chimerismwas significantly higher in granulocyte
than T cell fraction throughout the entire course, and themedian (mean) valueswere, respectively, 100% (96%)
versus 95% (83%), 100% (98%) versus 100% (89%), and 100% (98%) versus 100% (91%) at days 30, 60, and 90
after RIST. In a multivariate analysis, having received\2 types of chemotherapy regimens before RISTwas the
only factor that was significantly associated with low donor T cell chimerism (\60%) at day 30 (hazard ratio
[HR]: 6.1; 95% confidence interval [CI], 2.1-18.4; P\.01). The median percentage of donor T cell chimerism
at day 30 was 9% (0%-63%) in 5 patients who experienced graft failure, which was significantly lower than that
(97%; 15%-100%) in the rest of the patients (P\.01). No correlation was found between the kinetics of T cell
chimerism and the occurrence of acute or chronic GVHD (aGVHD, cGVHD). The stem cell source and the
addition of TBI or ATG were not associated with the degree of T cell chimerism, overall survival (OS) or
event-free survival (EFS). In a Cox proportional hazard model, low donor T cell chimerism of\60% at day
30 was associated with both poor OS (HR: 2.2; 95% CI, 1.1-4.5; P5 .02) and EFS (HR: 2.0; 95% CI, 1.1-3.8; P
5 .02). In conclusion, we found that 43% of the patients retained mixed donor T cell chimerism (\90% donor)
at day 30, whereas 92% achieved complete chimerism in granulocyte fraction. Low donor T cell chimerism of
\60%at day 30may predict a pooroutcome, and a prospective study to examine the value of early intervention
based on chimerism data is warranted.
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1148INTRODUCTION
Hematopoietic stem cell transplantation (HSCT)
with a reduced-intensity conditioning (RIC) regimen
has been increasingly used in patients with hemato-
logic diseases who cannot be candidates for conven-
tional HSCT because of age, medical comorbidities,
or prior failed myeloablative SCT. Many different
RIC regimens are currently in use, but most of them
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combination with other drugs including cyclophos-
phamide (Cy) [1], melphalan (Mel) [2], busulfan
[2,3], low-dose total body irradiation (TBI) [4], antith-
ymocyte globulin (ATG) [3], and alemtuzumab [5].
RIC regimens have been investigated in the hope of
reducing toxicity, whereas their engraftment potential
and antileukemia effect rely mainly on the expansion of
donor-derived cells and subsequent immune-mediated
graft-versus-leukemia (GVL) effects [6,7]. In this set-
ting, lineage-specific chimerism analysis to assess the
origin of lymphohematopoietic cells becomes particu-
larly important for identifying patients at risk for graft
failure/rejection, graft-versus-host disease (GVHD),
and relapse or progressive disease (PD) [4,8,9].
Because the posttransplantation chimerism status is
based on a fine balance between the cytotoxicity or im-
munosuppressive potential of the regimen used and the
recipient’s reserve immunocompetence, each RIC reg-
imen should be evaluated individually for chimerism
kinetics [1,4,10-13].
Compared with a regimen that includes Flu and
Me, it has been reported that the combination of Flu
and i.v. Bu was associated with improved survival in pa-
tients transplanted in remission, which was more fre-
quently associated with mixed chimerism [2].
However, very little information is currently available
on the clinical impact of lineage-specific chimerism
status in patients who are conditioned with a Bu-con-
taining RIC regimen. Therefore, we examined the cor-
relation between specific patterns of lineage-specific
chimerism and subsequent clinical outcomes.
PATIENTS AND METHODS
Patients and Transplantation Procedures
Weretrospectively reviewed themedical records of
117 patients who had various hematologic malignan-
cies and underwent allogenic HSCT with Bu-contain-
ing RIC at our hospital from January 2000 to
December 2006. The reasons for selecting RIC
regimens included older patient age, medical comor-
bidities, and prior failed myeloablative SCT. The
patients’ characteristics are summarized in Table 1.
The median age of the patients was 52 years (range:
29-68 years), and the hematologic malignancy in-
cluded acute myelogenous leukemia (AML) (n 5 23),
AML evolving from a myelodysplastic syndrome
(MDS) (n 5 16), acute lymphoblastic leukemia (ALL)
(n 5 5), malignant lymphoma (n 5 44), MDS (n 5
16), chronic myelogenous leukemia (CML) (n 5 9),
chronic lymphocytic leukemia (CLL) (n5 1), multiple
myeloma (MM) (n 5 1), and atypical CML (n 5 2).
The conditioning regimen consisted of Bu (oral 8
mg/kg or i.v. 6.4 mg/kg) and Flu (180 mg/m2, n 5
64) or cladribine (0.66 mg/kg, n5 53), with or without2-4 Gy TBI (n5 26) or antihuman T-lymphocyte im-
munoglobulin (Fresenius Biotech GmbH, Germany)
(ATG; 5-10 mg/kg, n 5 31).
In Japan, only bone marrow is permitted as a stem
cell source in transplantation from an unrelated
healthy volunteer donor. In the setting of nonmyeloa-
blative SCT from an unrelated donor, the sustained
engraftment rate has been reported to be lower for re-
cipients of bone marrow than for those given granulo-
cyte colony-stimulating factor-mobilized peripheral
blood mononuclear cells (G-PBMC) [14]. Therefore,
low-dose TBI was also added to the conditioning reg-
imen in 25 of the 32 patients who underwent reduced
intensity stem cell transplantation (RIST) from an un-
related bone marrow donor to facilitate engraftment.
Recipients of HLA-mismatched grafts tended to re-
ceive ATG-containing conditioning regimens (20 of
the 27 recipients of HLA-mismatched grafts [74%]
versus 11 of the 90 recipients of HLA-matched grafts
Table 1. Association between patients characteristics and
donor T-cell chimerism at day 30
T cell chimerism at day 30
Characteristics
Total
(n5117)
<60%
(n518)
$60%
(n599)
Patient age, years
Median (range) 55 (29-68) 57 (35-66) 54 (29-68)
<55 56 (48%) 6 (33%) 50 (51%)
$55 61 (52%) 12 (67%) 49 (49%)
Diseases type
Acute leukemia 44 (38%) 5 (28%) 39 (39%)
Lymphoma 46 (39%) 6 (33%) 40 (40%)
MDS/MPD 27 (23%) 7 (39%) 20 (20%)
Disease risk
High 91 (78%) 15 (83%) 76 (77%)
Low 26 (22%) 3 (17%) 23 (23%)
No. of prior chemotherapy regimens
$2 77 (66%) 6 (33%) 71 (72%)
<2 40 (34%) 12 (67%) 28 (28%)
Donor
Unrelated 32 (27%) 2 (11%) 30 (30%)
Related 85 (73%) 16 (89%) 69 (70%)
HLA
Match 90 (77%) 15 (83%) 75 (76%)
Mismatch 27 (23%) 3 (17%) 24 (24%)
Stem cell source
G-PBMC 81 (69%) 13 (72%) 68 (69%)
Bone marrow 36 (31%) 5 (28%) 31 (31%)
Conditioning regimen
2CdA/Bu 24 (21%) 4 (22%) 20 (20%)
2CdA/Bu/ATG 18 (15%) 4 (22%) 14 (14%)
2CdA/Bu/TBI 11 (9%) 1 (6%) 10 (10%)
Flu/Bu 38 (32%) 8 (44%) 30 (30%)
Flu/Bu/ATG 11 (9%) 1 (6%) 10 (10%)
Flu/Bu/ATG/TBI 2 (2%) 0 (0%) 2 (2%)
Flu/Bu/TBI 13 (11%) 0 (0%) 13 (13%)
Acute leukemia (n544): acute myelogenous leukemia (AML; n523), AML
evolving from amyelodysplastic syndrome (n516), and acute lymphoblas-
tic leukemia (ALL; n55); Lymphoma (n546): malignant lymphoma (44),
chronic lymphocytic leukemia (CLL; n51) and multiple myeloma
(MM; n51); MDS/MPD (n527): MDS n516 and MPD including chronic
myelogenous leukemia (n59) and atypical CML (n52); G-PBMC indicates
granulocyte colony-stimulating factor-mobilized peripheral blood mono-
nuclear cells; 2CdA, cladribine; Bu, busulfan; Flu, fludarabine; ATG, anti-
human T-lymphocyte immunoglobulin; TBI, total-body irradiation.
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sporin (CsA) alone (n 5 55), Cyclosporin with short-
term methotrexate (sMTX) (n5 38), tacrolimus alone
(n 5 13), or tacrolimus with sMTX (n 5 11).
In 81 of the 117 patients, the source of stem cells
was G-PBMC from a related donor, which contained
a mean of 3.3  106 CD341 cells/kg (range: 1.5-7.0
 106 CD341 cells/kg) and 8.7  107 CD31 cells/kg
(range: 6.4-86.1  107 CD31 cells/kg). The other 36
patients received related (n 5 4) or unrelated (n 5
32) bone marrow, which contained a mean of 2.9 
108 total nucleated cells (TNC)/kg (range: 0.97-6.53
 108 TNC/kg).
A total of 9 patients received donor lymphocyte
infusion (DLI), mainly after day 90, and all of them
receivedDLI for relapse of disease.Therewas nopatient
who received DLI for low donor T cell chimerism.
Informed consent was obtained according to the
Declaration of Helsinki.
Definitions
Graft failure was defined as (1) failure of absolute
neutrophil count (ANC) to surpass 500 /mm3 at day
30 after HSCT or (2) decrease in ANC\100 /mm3
at 3 determinations after the initial engraftment or
(3) absence of donor T cells (\5%) before relapse, dis-
ease progression, second HSCT, or death. The diag-
nosis and clinical grading of acute and chronic
GVHD (aGVHD, cGVHD) were performed accord-
ing to established criteria [15-17]. Complete remission
(CR) was defined as according to the International
Workshop Criteria in AML [18] and lymphoma [19]
patients. Low disease risk was defined as AML or
ALL in first CR, MDS-refractory anemia, and CML
in first chronic phase. All other diagnoses were classi-
fied as high risk.
Chimerism Analysis
We assessed donor-recipient chimerism by the
polymerase chain reaction (PCR)-based amplification
of a polymorphic short tandem repeat region. Chime-
rism was evaluated using peripheral blood samples on
days 30, 60, and 90 after transplantation. Samples were
separated using Ficoll-hypaque intomononuclear cells
and a precipitate that included red blood cells and
granulocytes. Mononuclear cells were further sepa-
rated into CD3-positive and -negative fractions with
immunomagnetic beads (CD3 Magnetic Particles-
DM, BD Pharmingen, San Diego, CA). Granulocytes
were collected by lysing red blood cells in the precipi-
tate. Briefly, DNAwas extracted from selected cells us-
ing QIAamp DNA Mini Kit (QIAGEN, Hilden,
Germany). Multiplex PCR was performed using
primer sets (AmpFISTR Identifiler Kit, Applied Bio-
systems, Foster City, CA). Five-color fluorescence de-
tection was performed on an ABI 3100-Avant GeneticAnalyzer (Applied Biosystems). For each STR allele,
the area under the curve for the corresponding signal
was automatically processed using GeneScan 3.7 soft-
ware (Applied Biosystems). The percentage of donor
cells was calculated as (area signal donor)/(area signal
donor 1 area signal recipient). The range of the error
of chimerism was regarded as 5% at our laboratory
(Heike et al., unpublished data).
Statistical Analysis
The chi-square test, Fisher’s exact test, and Pear-
son correlation coefficients were used to evaluate the
association of percent donor chimerism with various
clinical factors such as patient age at the time of
RIST (with 55 years as a cutoff), disease type (acute
leukemia, MDS/myeloproliferative disease [MPD],
lymphoma), disease risk (high, low), stem cell source
(G-PBMC, bone marrow), serologic HLA matching
(match, mismatch), and conditioning with TBI (yes,
no) or ATG (yes, no).
Overall survival (OS) was defined as the time be-
tween stem cell infusion to death from any cause.
Event-free survival (EFS) was defined as the time
from stem cell infusion to graft failure, PD, or nonre-
lapse mortality (NRM), whichever occurred earlier.
OS and EFS were estimated by the Kaplan-Meier
method [20]. The log-rank test and the generalized
Wilcoxon test were used to compare the probabilities
of survival after HSCT over time across patient sub-
groups. Multiple Cox regression models were used
for multivariate risk factor analysis for OS and EFS.
Clinical factors evaluated in the OS and EFS analyses
were donor T cell chimerism at day 30 (with 60% as
a cutoff), patient age at the time of RIST, disease
type, disease risk, stem cell source, HLA matching,
and conditioning. Logistic regression models were
used for multivariate risk factor analysis for low donor
T cell chimerism (\60%) at day 30. Clinical factors
evaluated for the risk of low donor T cell chimerism
at day 30 were number of prior chemotherapy regi-
mens ($2,\2) and donor type in addition to the vari-
ables mentioned above. We considered 2-sided P-
values of\.05 to be statistically significant. Statistical
analyses were performed with SAS version 8.2 (SAS
Inc., Cary, NC).
RESULTS
Kinetics of Chimerism
Whereas 43% of the patients retainedmixed donor
chimerism (\90% donor) in the T cell fraction, 92%
achieved complete chimerism ($90%) in the granulo-
cyte fraction at day 30 after RIST (Figure 1). In the pe-
ripheral blood mononuclear cell (PBMC) fraction,
72% of the patients achieved complete chimerism
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cantly higher in granulocyte than T cell fraction
throughout the entire course, and the median (mean)
values were, respectively, 100% (96%) versus 95%
(83%), 100% (98%) versus 100 % (89%), and 100%
(98%) versus 100% (91%) at days 30, 60, and 90, re-
spectively after RIST (Figure 2).
In univariate and multivariate analyses (Table 2),
having received\2 types of chemotherapy regimens
before RIST was the only factor that was significantly
associated with low donor T cell chimerism (\60%) at
day 30 (hazard ratio [HR]: 6.1; 95% confidence inter-
val [CI], 2.1-18.4; P\ .01). Non-TBI regimens and re-
lated donor also tended to be associated with lower
donor T cell chimerism.
Graft Composition and Donor Chimerism
By examining the impact of graft composition of
G-PBMC on donor chimerism, we found that in-
creases in TNC and CD31 T cells contents paralleled
the increase in donor T cell chimerism at day 30 (P\
.03 and P\ .05, respectively). The same relationship
was observed between CD341 cell contents and gran-
ulocyte chimerism (P 5 .06). In patients who received
bone marrow, a higher number of TNC infused was
associated with a higher level of donor T cell chime-
rism at day 30 (P\ .01).
Figure 1. Distribution of chimerism status at day 30 after RIST.
Figure 2. Kinetics of chimerism status after RIST (mean percentages of
donor chimerism levels). Percent donor cell chimerism was significantly
higher in granulocyte than T cell fraction throughout the entire course,
and the mean values were, respectively, 96% versus 83%, 98% versus
89 %, and 98% versus 91% at days 30, 60, and 90 after RIST.Association between Donor T Cell Chimerism
at Day 30 and RISTOutcome
Graft failure
The median (mean) percentage of donor T cell
chimerism at day 30 was 9% (18%) (0%-63%) in 5 pa-
tients who experienced graft failure, which was signif-
icantly lower than those in the other patients (97%
[86%], 15%-100%, P\ .01), as shown in Figure 3.
Day 30 T cell chimerism below 60% was associated
with a significantly increased risk of graft failure (Ta-
ble 3). Among the 5 patients who experienced graft
failure, 4 had achieved complete donor chimerism at
day 30 when evaluated in the granulocyte fraction.
Whereas 4 of the 5 patients (80%) who experi-
enced graft failure received HLA-mismatched grafts,
23 of the 112 patients (21%) who did not experience
graft failure received HLA-mismatched grafts (P 5
.01). In a multivariate analysis, however, neither day
30 T cell chimerism below 60% nor HLA mismatch
was associated with an increased risk of graft failure.
Among 18 patients with\60% donor T cell chime-
rism at day 30, HLA mismatch was significantly asso-
ciated with an increased risk of grafts failure (3 of 3
who received HLA-mismatched graft versus 1 of 15
who received HLA-matched grafts, P5 .005). In con-
trast, HLA mismatch was not associated with an in-
creased risk of graft failure in 99 patients with 60%
or more donor T cell chimerism at day 30 (1 of 24
Table 2. Factors affecting low donor T cell chimerism (<60%)
at day 30
Univariate analysis Multivariate analysis
Characteristics Odds ratio (95% CI) P Odds ratio (95% CI) P
Patient age, years
<55 1
$55 2.04 (0.71 - 5.87) 0.19
Disease type
Lymphoma 1
MDS/MPD 2.33 (0.69 - 7.87) 0.17
Acute leukemia 0.86 (0.24 - 3.03) 0.81
Disease risk
Low 1
High 1.51 (0.40 - 5.69) 0.54
No. of prior chemotherapy regimens
$2 1 1
<2 5.07 (1.73-14.83) <0.01 6.08 (2.01–18.41) <0.01
Stem cell source
G-PBMC 1
Bone marrow 0.84 (0.28 - 2.57) 0.77
Donor
Unrelated 1 1
Related 3.48 (0.75-16.08) 0.11 4.21 (0.86–20.49) 0.08
HLA
Match 1
Mismatch 0.63 (0.17 - 2.34) 0.49
TBI
No 1 1
Yes 0.17 (0.02 - 1.38) 0.10 0.13 (0.02–1.05) 0.06
ATG
No 1
Yes 1.08 (0.35 - 3.32) 0.89
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who received HLA-matched grafts, P 5 .24).
GVHD
Grade II-IV aGVHD occurred in 54 patients
(46%), and cGVHD occurred in 63 patients (64%).
No correlation was found between the kinetics of T
Figure 3. Donor T cell chimerism levels at day 30 in patients with or
without subsequent graft failure. Five of the 117 patients (4%) who ex-
perienced graft failure had a significantly lower donor T cell chimerism
level than the other engrafted patients (n 5 112) (donor T cell chime-
rism, median 9% [range: 0%-63%] versus 97% [range: 15%-100%], re-
spectively) (p \ .01). Horizontal lines, median; boxes, 25-75
percentile; vertical lines, 10-90 percentile; circles, individual data outside
the 10-90 percentile.
Table 3. Association between donor T-cell chimerism at day
30 and clinical outcome
T-cell chimerism
at day 30
Outcome
Total
(n5117)
<60%
(n518)
$60%
(n599) P
Graft failure
No 112 (96%) 14 (78%) 98 (99%) <0.01
Yes 5 (4%) 4 (22%) 1 (1%)
Acute GVHD
0-I 64 (55%) 11 (61%) 53 (54%)
II-IV 53 (45%) 7 (39%) 46 (46%) 0.55
Chronic GVHD*
No 36 (36%) 7 (50%) 29 (34%) 0.25
Yes 63 (64%) 7 (50%) 56 (66%)
NRM (at 1 year) 11.0% 11.1% 10.9% 0.26
PD (at 1 year) 27.3% 22.6% 28.1% 0.45
OS (at 1 year) 78.0% 65.7% 80.3% 0.02
EFS (at 1 year) 61.8% 55.6% 62.8% 0.02
GVHD indicates graft-versus-host disease; NRM, non-relapse mortality;
PD, relapse or progressive disease; OS, overall survival; EFS, event-free
survival;
*Proportion of patients with chronic GVHD was assessed among 99
evaluable patients.cell chimerism and the occurrence of aGVHD or
cGVHD, as shown in Table 3.
NRM and PD
Nineteen patients experienced NRM, with a 1-
year probability of 11% (Table 3). No correlation
was found between T cell chimerism at day 30 and
the incidence of NRM.
PD was observed in 39 patients, with a 1-year
probability of 27% (Table 3). No correlation was
found between T cell chimerism at day 30 and the in-
cidence of PD.
Cause of death
Among the 18 patients who had\60% donor T
cell chimerism at day 30, 7 (39%) died of PD and 4
(22%) died of NRM, including bacteria sepsis (n 5
2), pneumonitis (n 5 1), and secondary carcinoma (n
5 1). In contrast, among the remaining 99 patients
who achieved 60% or more donor T cell chimerism,
21 (21%) died of PD and 15 (15%) died of NRM, in-
cluding pneumonitis (n 5 8), sepsis (n 5 3), hemor-
rhage (n 5 1), GVHD (n 5 1), cerebral infarction (n
5 1), and unknown cause (n 5 1).
OS and EFS
Seventy patients (60%) are currently alive at a me-
dian follow-up of 1040 days after RIST (range: 153-
2535). The 1-year probabilities of OS and EFS among
all of the patients were 78% and 62%, respectively. As
shown in Figure 4, OS was significantly better in pa-
tients who achieved 60% or more donor T cell chime-
rism at day 30 than in those who did not (P 5 .02). In
a Cox proportional hazard model, low T cell donor
chimerism (\60%) at day 30 was associated with
poor OS (HR: 2.2; 95% CI, 1.1-4.5; P 5 .02) and
EFS (HR: 2.0; 95% CI, 1.1-3.8; P 5 .02) adjusted
for other significant prognostic factors (Table 4). In
addition, high-risk disease and patient age ($55 years)
were associated with an increased risk of poor EFS
(HR: 2.4; 95% CI, 1.2-5.0; P 5 .02, HR: 1.8; 95%
CI, 1.1-3.0; P 5 .03, respectively) (Table 4).
Figure 4. OS stratified according to donor T cell chimerism at day 30.
OS was significantly better in patients who achieved 60% or more donor
T cell chimerism at day 30 than in those who did not (P 5 .02).
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In this retrospective study of RIST with Bu, we
showed that 43% of the patients retained mixed donor
T cell chimerism (\90%), whereas 92% achieved
complete chimerism in the granulocyte fraction, which
was consistent with previously published observational
studies in RIST [4,10,11,13,21]. Furthermore, we
showed that low donor T cell chimerism of\60% at
day 30 predicted poor OS and EFS, which suggests
that the kinetics of T cell chimerism are important af-
ter Bu-containing RIST.
Consistent with other reports, we found that the
induction of complete chimerism in T cell fraction
after a Bu-containing regimen was rather slow, and
granulocyte engraftment was earlier than T cell en-
graftment compared to patients who received RIC
regimens containing a combination of Flu and Mel
[10]. When the combination of Cy and Flu was
used for RIST conditioning, full donor chimerism
was achieved earlier in T cells than in myelogenous
cells [1,22]. Interestingly, when alemtuzumab was
used in a RIC regimen, 58% retained mixed donor
chimerism at day 90 after RIC [13]. This may be be-
cause of the fact that alemtuzumab remained in the
peripheral circulation long after RIST, which sup-
pressed not only host but also donor lymphocytes.
Based on these reports, we suspected that a Cy-con-
taining regimen suppresses host granulocytes less in-
tensely than a Bu-containing regimen, whereas
a Mel-containing regimen suppresses host lympho-
cytes more intensely than a Bu-containing regimen.
The only significant variable associated with
a lower level of donor T cell chimerism at day 30
was having received \2 regimens of chemotherapy
pretransplant in our results. This result was consistent
with previous reports [4,10]. When a patient is treated
Table 4. Multivariate analysis: factors associated with clinical
outcome
Outcome Variable Harzard ratio 95% CI P
OS
Donor T-cell chimerism
at day 30
$60% 1
<60% 2.25 1.13–4.47 0.02
EFS
Donor T-cell chimerism
at day 30
$60% 1
<60% 2.05 1.10–3.81 0.02
Patients age, years
<55 1
$55 1.80 1.07–3.04 0.03
Disease risk
Low 1
High 2.44 1.19–5.01 0.02
Clinical factors evaluated in the OS and EFS analyses were donor T-cell
chimerism at day 30 (with 60% as a cutoff), patient age at the time of
RIST, disease type, disease risk, stem cell source, HLAmatching and con-
ditioning.with RIST, such as our low-dose Bu-containing regi-
men, prior chemotherapy may facilitate the achieve-
ment of higher levels of donor T cell chimerism by
decreasing the recipient immunocompetence.
In previous reports there has been some contro-
versy regarding whether there are any differences in
the levels of donor T cell chimerism after RIST with
or without low-dose TBI [11,13]. In our study with
Bu-containing regimens, regimens that included ad-
ditional low-dose TBI tended to offer higher donor
T cell chimerism in a multivariate analysis. However,
there was no correlation between ATG-conditioning
regimens and donor T cell chimerism at day 30,
which was consistent with other regimens [13].
This might be because of the lower dose of ATG
(Fresenius, 5-10 mg/kg) in our regimens compared
to other studies that utilized the same ATG prepara-
tion (Fresenius, 40-90 mg/kg) [23,24]. Alternatively,
this might be simply because of the small number
of patients who received ATG in our study.
In previous reports, recipients of G-PBMC after
RIST showed higher percentages of donor T cell chi-
merism than those who received bone marrow [4,25],
which was not confirmed in our study. With regard
to regimens that include Bu, no previous large-scale
study has analyzed the correlation between the type
of stem cell source and T cell engraftment. When
low-dose Bu is contained in the RIC regimen, the
stem cell source may no longer influence the level of
T cell chimerism. Alternatively, this may be because
of the fact that most of the bone marrow recipients
in our study also received an additional 2-4 Gy TBI.
There was a trend toward a decreased risk of low donor
T cell chimerism in recipients of unrelated grafts, al-
though the difference was not significant. We specu-
late that a lower probability of low donor T cell
chimerism might be because of the addition of low
dose TBI for patients who underwent unrelated
HSCT.
Patients who received G-PBMC showed an in-
crease in TNC and CD31T cells that paralleled an in-
crease in donor T cell chimerism at day 30 after RIST
in our study. The same relationship was observed be-
tween CD341 cell contents and granulocyte chime-
rism. Baron et al. [26] reported that higher numbers
of donor T cells and CD341 progenitor cells in the
grafts were associated with higher levels of day 28 do-
nor T cell chimerism. Similarly, Carvallo et al. [22] re-
ported that higher levels of CD341 progenitor cells in
the grafts were associated with higher levels of donor
myeloid chimerism early after RIST.
In this study, donor T cell chimerism levels of be-
low 60% early after RIST were significantly associated
with an increased risk of graft failure. It has been re-
ported that patients with\50% donor T cell chime-
rism early after nonmyeloablative HSCT were more
likely to have graft failure than those with more than
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RIC, Mattsson et al. [21] reported that 2 of the 8 pa-
tients who had .50% recipient T cells on day 28
had graft failure or rejection, whereas this was not
seen in any of the 22 patients with\50% recipient T
cells. Lower donor natural killer NK-cell chimerism
after Bu-containing RIST was associated with an in-
creased risk of graft failure [4,27]. Although significant
associations of low donor T cell chimerism and HLA
mismatch with graft failure disappeared in our multi-
variate model, our data suggested that HLA mismatch
was an important predictor of graft failure only in pa-
tients with\60% donor T cell chimerism at day 30.
The current study demonstrated that patients at high
risk of graft failure could be identified by chimerism
analysis at day 30 in T cell fractions, but not in granu-
locyte fractions, and that chimerism analysis at day 30
after Bu-containing RIST may allow early interven-
tions aimed at reversing graft failure.
Our results suggest that low donor T cell chime-
rism of \60% at day 30 may predict a poor out-
come, although levels of donor T cell chimerism
were not associated with NRM PD. In our study,
the levels of donor T cell chimerism were not asso-
ciated with aGVHD or cGVHD, although some re-
ports have stated that donor T cell chimerism was
associated with the risk of GVHD [1,4,13,19,28]. It
is still controversial whether or not achievement of
complete donor T cell chimerism is needed to im-
prove OS and reduce the relapse risk in patients
who undergo RIST. Baron et al. [9] suggested that
the assessment of donor chimerism levels helps to
identify patients who are at higher risk of relapse af-
ter nonmyeloablative HSCT. High donor chimerism
levels among immune competent cells including T
cells and NK cells might be a surrogate for a high
graft-versus-tumor effect, and a fractionated chime-
rism analysis may be useful for detecting and quan-
tifying minimal residual disease after RIST. In
a small case series of Bu-containing RIST, mixed
donor chimerism was associated with an increased
risk of relapse and a worse prognosis [12,29]. In con-
trast, among patients who underwent RIST that
contained Flu, Bu, and alemtuzumab, those who
showed mixed donor chimerism beyond day 100
were associated with an improved OS and a lower
incidence of GVHD and NRM, without any effect
on the relapse risk [13]. Further studies are needed
to determine whether the achievement of complete
chimerism after RIST is beneficial with less risk of
PD and/or more risk of NRM.
In conclusion, within the limitations of a retrospec-
tive study, we found that the percentage of donor chi-
merism was significantly higher in granulocyte than T
cell fraction throughout the entire course after
Bu-containing RIST. Low donor T cell chimerism
of\60% at day 30 may predict a poor outcome, anda prospective study to examine the value of early inter-
vention based on chimerism data is warranted.
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